Simulations Plus updates its guidance, shares react to recent acquisitions

Simulations Plus has refined its financial outlook after integrating recent acquisitions in its software and consulting portfolio. The Nasdaq-listed company adjusts expectations while investors watch how the enlarged group performs against peers in the life sciences software space.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 22:44.

Simulations Plus (US82834F1012) refines its short-term outlook for revenue and margins as integration of its acquired units progresses, according to its investor communications and recent analyst commentary on the Nasdaq-listed shares. The updated guidance reflects how management now sees the balance of software and consulting revenue after the latest portfolio adjustments.

Guidance and acquisitions in focus

Simulations Plus Inc. operates on Nasdaq under the ticker SLP, and management recently reiterated its focus on profitable growth while folding in the assets acquired over the past years, including consulting-heavy businesses in the drug development space, in an outlook discussion on its investor relations materials and call notes. The company has historically combined organic growth from its flagship simulation platforms with bolt-on deals to broaden its exposure to pharmaceutical and biotech customers.

As part of its latest guidance refinement, Simulations Plus highlights expected revenue contributions from its software licenses and consulting engagements, balancing recurring and project-based income in a way analysts can model more precisely for the coming fiscal periods. The integration of acquired teams and technology platforms is central to how the company frames its adjusted expectations for operating margins and cash generation, and its investor communications stress disciplined capital allocation alongside continued investment in research and development.

Analyst views and peer comparisons

Coverage from specialized healthcare and technology analysts tracks Simulations Plus against peers in the life sciences software cluster, including companies offering modeling tools and data platforms to pharma clients, and recent notes describe expectations for mid- to high-single-digit organic growth with upside from deeper adoption of the firm's simulation workflows. In these reports, analysts emphasize the company's position at the intersection of quantitative pharmacology, regulatory science, and cloud-based software delivery, as well as the importance of maintaining customer retention rates and expanding usage within existing accounts.

Analyst consensus data shows a mix of ratings ranging from Hold to Buy, with price targets reflecting both the growth potential of the company's core platforms and the valuation premium often assigned to niche application software providers in healthcare and life sciences. Commentators also point to the firm's exposure to regulatory changes and budget cycles at large pharma clients, noting that the shares can trade with some sensitivity to broader sector sentiment and spending plans in drug development technology.

What Simulations Plus sells

Simulations Plus generates revenue primarily by offering specialized software and related services that support drug discovery and development workflows for pharmaceutical and biotechnology companies, regulatory agencies, and academic institutions. Its platforms provide quantitative tools for modeling pharmacokinetics, pharmacodynamics, and other aspects of how candidate drugs behave in the body, and consulting teams apply the technology in tailored studies.

Where the stock trades today

Simulations Plus shares trade on Nasdaq in U.S. dollars, and the stock recently changed hands around typical levels for its current market capitalization range, with investors watching both fundamental updates and broader moves in life sciences and software indices.

Simulations Plus at a glance

• Company: Simulations Plus Inc.
• ISIN: US82834F1012
• WKN: 914192
• Ticker: SLP
• Trading venue: Nasdaq
• Price (as of 2026-06-26, 20:40): 47.50 USD
• Market cap: 960,000,000 USD (as of 2026-06-26)
• Sector / industry: Healthcare technology and life sciences software
• Index membership: None of the major headline indices such as S&P 500 or Nasdaq-100
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.